Drug injection may cause substantial rise in bacterial heart infections

Image
ANI
Last Updated : Jan 28 2019 | 12:45 PM IST

A new study now finds that people who inject drugs have a significant increase in the risk of infective endocarditis. It is a serious infection of the lining of the heart and is possibly linked to increased use of the opioid hydromorphone.

The study is published in Canadian Medical Association Journal (CMAJ).

Speaking about the study, first author Dr, Matthew Weir wrote, "We observed a substantial increase in the risk of infective endocarditis among people who inject drugs, which is associated with hydromorphone's increasing share of the prescription opioid market."

The study further found that although admission rates for people who inject drugs were stable over the study period, the risk of infective endocarditis increased from 13.4 admissions every three months (fourth quarter 2011) to 35.1 admissions every three months in the period afterwards.

Whereas the percentage of opioid prescriptions attributed to controlled-release oxycodone declined rapidly when it was removed from the market by its manufacturer in the fourth quarter of 2011, hydromorphone prescriptions increased from 16 per cent at the start of the study to 53 per cent by the end.

The researchers expected that an increase in risk of infective endocarditis would occur when controlled-release oxycodone was removed from the Canadian market; however, they found that the rise began before removal.

Speaking about it, co-author Dr. Michael Silverman said, "Although our observations do not support our hypothesis that the loss of controlled-release oxycodone increased the use of hydromorphone, they do support our suspicion that hydromorphone may be playing a role in the increasing risk of infective endocarditis."

The increase in the risk of infective endocarditis is consistent with the findings of other studies, but the observed timing of the increase was novel.

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Jan 28 2019 | 11:40 AM IST

Next Story